



维亚生物科技控股集团  
Viva Biotech Holdings  
Stock Code: 1873.HK

NEWSLETTER Issue 4  
Feb - Jun 2020



Company News

Viva BioInnovator (VBI) Successfully Held 1st Demo Day



On 11 June 2020, Viva BioInnovator (VBI) successfully held its 1st Demo Day e-congress. Among nearly 50 incubation portfolio companies from the VBI platform, 8 startup companies attended this event, namely Forkhead Bio Therapeutics, DTx Pharma, Epican Technology, Acelink Therapeutics, TechnoDerma, VersaPeutics, ArthroSi Therapeutics and Totient, covering numerous fields including hereditary nephropathy, gout, diabetes, dermatological diseases, spinal cord injuries and early diagnosis of oncology.

Over 200 domestic and overseas top-tier investors, representatives of investment institutions, R&D representatives of pharmaceutical companies, etc. participated in the event and conducted in-depth communication with company founders in an interactive way online. Investor representatives from Sequoia Capital, Kaitai Capital, WisdoMont Asset Management, LH Ventures, etc., who had invested in those invited incubated companies, were also invited to VBI Demo Day. The previous investors shared their investment logics in aspects of technical path, market prospects and competitive strengths of each project.

After this Demo Day, each invited startup company has connected with 3 to 5 investors in average and conducted follow-up communication. In the future, VBI will continue organizing Demo Day events regularly, aiming to provide founders of the incubated companies with a better platform for financing, communication and exhibition, and further enhance the innovative biopharmaceutical investment ecosystem which centers on Viva Biotech and creating more values for companies on the platform, endeavoring to realize a win-win circumstance.



Sichuan Viva and Sichuan Chunqiu Entered Into Construction Contract to Build Viva Biotech New Drug Incubation Center



On 8 May 2020, Sichuan Viva, a wholly-owned subsidiary of the Company, entered into a construction contract with Sichuan Chunqiu (the Contractor), pursuant to which the Contractor had agreed to undertake construction work for Viva Biotech New Drug Incubation Center for a contract sum of approximately RMB149.8 million (subject to adjustments).

Sichuan Viva has obtained the land use right for a land parcel with a total site area of 33,607.94 square meters located in Wenjiang, Chengdu for the construction of Viva Biotech New Drug Incubation Center. Viva Biotech New Drug Incubation Center will offer the Group new biologics manufacturing facilities as well as additional incubator space for its incubation of innovative drug R&D projects. The Group expects that Viva Biotech New Drug Incubation Center will allow the Group to further strengthen its contract research and manufacturing capabilities and meet its business development needs.



## Viva Biotech Signed with Zhangjiang Headquarters Park(张江总部园) to Accelerate the Industrialization of Drug Innovation

On 15 April 2020, the opening ceremony of Zhangjiang Headquarters Park(张江总部园) was successfully held. Dr. Delin Ren, executive Director and the president of Viva Biotech was invited to attend the press conference and participated in the signing ceremony on behalf of the Company. The selection of establish and take root the headquarter of Viva Biotech Holdings in Zhangjiang Headquarters Park(张江总部园) will help the Group to reduce operating costs, systematize layout and promote development in scale, and provide a sustainable operation and R&D site for the follow-up development of high-potential biotechnology enterprises on the incubation platform.



## Market Recognition

### Viva Biotech Was Granted the Best Medical Service Listed Company

On 27 May 2020, based on the analysis of the current situation of investment and financing in the medical industry, CHC medical consulting and CITIC Securities Co., Ltd. online released the "2019 China Healthcare Industry Investment and Financing Honor List".

As a world-leading structure-based drug discovery service provider, Viva Biotech was listed and granted the Best Medical Service Listed Company. By combining the conventional cash-for-service (CFS) and unique equity-for-service (EFS) approaches, Viva Biotech provides drug discovery and incubation services to biotech companies with high potential worldwide.



### Viva Biotech Included as Constituent Stock of Hang Seng Composite Index and Other 6 Indexes Becoming an Eligible Stock of Shenzhen-Hong Kong Stock Connect



恒生指數  
HANG SENG INDEXES

深港通  
SHENZHEN CONNECT

On 21 Feb 2020, Viva Biotech Holdings was included as a constituent stock of seven indexes, namely Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK HK Companies Index and Hang Seng SCHK ex-AH Companies Index. The constituent changes will be made to the Hang Seng Family of Indexes with effect from 9 March 2020. Included in the Hang Seng Composite Index also means that Viva Biotech will be selected as an eligible stock of the China-Hong Kong Stock Connect in accordance with the selection requirements of the Shenzhen-Hong Kong Stock Connect.

The inclusion of Viva Biotech as a constituent stock of Hang Seng Composite Index and other important indicatable indexes in the Hong Kong capital market was another milestone after being included in the Hang Seng Hong Kong-Listed Biotech Index in December 2019. It reflects the full recognition of Viva Biotech's overall performance in the capital market and its great influence in the healthcare industry, which will further help to enhance the awareness of the Company among domestic and foreign investors.





### Research & Development Process



#### **ABM Therapeutics Announced ABM-1310 Phase I Clinical Trial in US Successfully Medicated the First Patient**

On 22 June 2020, ABM Therapeutics, a company co-incubated by Viva BioInnovator, a biomedical innovator focused on the research and development of small molecule drugs that can cross the blood-brain barrier, announced that the Phase I clinical trial of its ABM-1310 in the United States has successfully enrolled and medicated the first patient. ABM-1310, the company's first drug candidate, is an oral, high-selectivity, high-water-solubility, and high-BBB permeability small molecule BRAF inhibitor. It has shown unique advantages in animal models in preclinical studies.

The enrollment and medication of the first patient is another important event following the US FDA clinical trial approval of ABM-1310, a significant milestone both for the ABM-1310 project itself and for the majority of patients.

### Investment Progress



#### **QurAlis Completed Series A Funding of USD\$42 Million to Focus on the Development of Innovative Treatments for Neurodegenerative Diseases**

On 13 May 2020, QurAlis, a platform company co-incubated by Viva BioInnovator, recently announced the completion of USD\$42 million Series A round funding, raising over USD\$50 million in total. As a biotechnology company focused on the precise treatment of amyotrophic lateral sclerosis (ALS) and other neurological disease, QurAlis will use this round of financing to further develop new therapies for ALS and genetically related frontotemporal dementia (FTD). As of now, there is no effective cure for neurodegenerative diseases on the market.



#### **QureBio Completed Series A+ Funding of Tens of Millions to Promote the Pre-clinical Development of Tumor Immunity DAB Drug**

On 10 April 2020, QureBio, a company co-invested and co-incubated by Viva BioInnovator, recently announced the completion of series A+ funding of tens of millions by SCGC Health Industry Fund. QureBio will mainly use this round of financing to advance the pre-clinical development of the company's Q-1802 and Q-1801 projects. Project Q-1802 is dual-target immunotherapy for solid tumors such as gastric cancer, 3 pilot batches production have been completed so far, and is expected to complete both NMPA and FDA application this year. Project Q-1801 is a bispecific antibody drug targeting the tumor microenvironment signaling pathway, which can mobilize both innate and adaptive immunity mechanisms to kill the tumor. At present, the company is actively developing the technology of this drug and expecting to complete the clinical application in 2021.



## About Viva Biotech

#### Listing Date

2019.05.09

#### Price (2020.7.6)

HKD 8.96

#### 52 WK Range

HKD 3.50 – 9.84

#### Market Cap (2020.7.6)

HKD 14.85B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of December 31, 2019, Viva Biotech had provided drug discovery services to 438 biotechnology and pharmaceutical customers worldwide, worked on over 1,200 independent drug targets, delivered over 13,700 independent protein structures, and incubated a total of 46 early stage R&D projects.

#### Investor & Media Enquiries

Viva Biotech Holdings website: [www.vivabiotech.com.cn](http://www.vivabiotech.com.cn)

For further information, please contact:

Email : [ir@vivabiotech.com](mailto:ir@vivabiotech.com)

[VivaBiotech.hk@pordahas.com](mailto:VivaBiotech.hk@pordahas.com)

Tel : 852-3150 6788

